On April 8, 2020 Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, reported that Lorence Kim, M.D., Chief Financial Officer will participate in the 19th Annual Needham Healthcare Conference on April 14th at 10:40 a.m. ET (Press release, Moderna Therapeutics, APR 8, 2020, View Source [SID1234556214]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for 90 days following the presentation.

On April 8, 2020 Seattle Genetics, Inc. (Nasdaq:SGEN) reported that management will participate in a fireside chat at the Needham Healthcare Conference on Tuesday, April 14, 2020 at 12:00 p.m. Eastern Time (Press release, Seattle Genetics, APR 8, 2020, View Source [SID1234556213]). The conference will be held in a virtual meeting format. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 8, 2020 4SC AG (4SC, FSE Prime Standard: VSC) reported that its Investigational New Drug (IND) application for domatinostat in combination with avelumab (Bavencio) has been accepted by the U.S. Food and Drug Administration (FDA) (Press release, 4SC, APR 8, 2020, View Source [SID1234556210]). The MERKLIN 2 study is a Phase II clinical study evaluating domatinostat in combination with avelumab in patients with advanced MCC whose disease has progressed on anti-PD-(L)1 antibody therapy. Avelumab is an anti-PD-L1 antibody co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MCC is a relatively rare, but highly aggressive and immunogenic type of non-melanoma skin cancer. In 2017, avelumab was the first anti-PD-(L)1 antibody approved in both the EU and US for treatment of metastatic MCC. Since 2017, anti-PD-(L)1 antibodies have become the standard of care in metastatic MCC globally. However, a majority of patients may become refractory or relapse on this treatment, and currently do not have access to effective subsequent therapeutic options, which is reflected by a high mortality rate. The MERKLIN 2 study seeks to address this high unmet medical need.

Jason Loveridge, Ph.D., CEO of 4SC: "We are delighted to be working with Merck KGaA, Darmstadt, Germany and Pfizer as pioneers of immune checkpoint blockade to address the high unmet medical need in patients with advanced MCC disease and now that our IND is open, we can go forward with this study in the US as soon as practically possible".

On April 8, 2020 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported that Daniel P. Gold, Ph.D., president and chief executive officer, will present an overview and business update at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14th at 2:50 PM Eastern Time (Press release, MEI Pharma, APR 8, 2020, View Source [SID1234556206]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of MEI Pharma’s website at View Source

An archived replay of the webcast will be available on MEI Pharma’s website for at least 30 days after the live event concludes.

On April 8, 2020 Eli Lilly and Company (NYSE: LLY) reported that it will announce its first-quarter 2020 financial results on Thursday, April 23, 2020 (Press release, Eli Lilly, APR 8, 2020, View Source [SID1234556204]). Lilly will also conduct a conference call on that day with the investment community and media to further detail the company’s financial performance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will begin at 9 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly’s website at View Source A replay will also be available on the website following the conference call.